Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The acquisition positions Sanofi alongside Lilly, Bristol Myers Squibb, and AbbVie in pursuing next-generation B-cell depletion for autoimmune diseases.…
Sanofi is building on its immunology ambitions by acquiring an early clinical Dren Bio drug candidate that offers a potential first-in-class approach to…
Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts. The Fierce Biotech article references Sanofi's earlier Dren Bio acquisition as the…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Sanofi agreed to acquire Dren Bio's DR-0201, a targeted bispecific myeloid cell engager for deep B-cell depletion, for $600M upfront plus $1.3B in milestones. Broadens Sanofi's immunology pipeline; DR-0201 is in Phase 1 for autoimmune diseases. Completed May 27, 2025.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Dren Bio, Inc. (this deal) | 2025 | $1.9B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2025 deals · Sanofi SA deals · Immunology deals